Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
3 Ankur Mehta, Bhavin Bhagat, Nirav Mehta
Analysts
8 Alankar Garude, Amey Chalke, Bhavika Singhvi, Gopal Bhatt, Maulik Varia, Pratik Dharamshi, Rahul Jeewani, Siddharth Goddanti
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹422 crores | 21.9% YoY growth vs ₹347 crores in Q1 FY26; ex-acquired portfolio (Wokadine) growth at 21.4% |
| India Business Revenue | 97% of total | Grew 22.7% YoY, nearly 2x IPM growth of 11.6%; international flat in quarter |
| EBITDA | ₹93 crores | 33.5% YoY growth vs ₹70 crores; margin expanded 190 bps YoY to 22.0% |
| PAT | ₹60 crores | 30.1% YoY growth vs ₹46 crores; margin at 14.2%, up 90 bps YoY from 13.3% |
| Chronic & Semi-chronic Share | 73.4% | Of total portfolio, driving growth through specialist segmentation |
| Volume Growth | 6.3% | vs IPM 1.3% (May-June 2026 Pharmatrac), roughly 5x market rate |
| Price-Led Growth | 8.7% | vs IPM 5.6% (May-June 2026), reflecting brand pricing power |
| New Product Introduction Growth | 3.4% | vs IPM 2.9% (May-June 2026), on back of cross-selling via existing field force |
| Depreciation & Amortization | ₹13.4 crores | Up from ₹10 crores in Q1 FY26, driven by amortization of Wokadine brands (~₹2.5 cr/quarter over 10 years) and Bayer brand acquisition |
| IPM Ranking | 26th | Improved 3 positions from 29th over past year; fastest-growing pharma among Top 30 |
Geographic & Segment Commentary
- India: Revenue of ₹410 crores approximately (97% of total), growing 22.7% YoY versus IPM at 11.6%. Growth was broad-based across volume, price, and new introductions. Management reiterated India remains the core focus with 90%+ share expected even after 5 years; international business likely to move from ~3% to higher single-digit in 3-4 years.
- Women's Healthcare: Grew ~23.3% versus IPM 9.4% — nearly 2.5x market. Ranked 5th in IPM. Includes hormone portfolio (about 30% of women's health revenue) now supported by new EU GMP manufacturing facility; new dedicated IVF task force established in April 2026 with early traction noted.
- Urology: Grew 27.6% versus IPM 14.9%, ranked 9th in IPM. Strong component of chronic portfolio strategy.
- Cardiometabolic: Grew at 1.7x IPM rate, ranked 20th in IPM despite late entry; ranked Top 10 in consolidating new business. Launched Noklot brand (from BioZydus acquisition) in June 2026.
- Pain Management: Grew 1.54x IPM rate, ranked 5th in IPM.
Company-Specific & Strategic Commentary
- EU GMP Hormone Facility: Commercialized June 30, 2026 — India's most advanced women's hormone manufacturing facility with INR130 crores capex. Serves hormonal disorders, fertility care, menopause, and HRT segments with multiple dosage forms (tablets, soft gels, ointments, gels). Asset turnover expected <1x in FY27, ramping to 2-3x within 3 years; international dossiers filing by Nov-Dec 2026, with exports beginning FY28-29.
- Wokadine Integration: Acquired from Dr. Reddy's on last day of FY26 (INR97 crores + GST, external revenue INR28-30 crores plus INR20 crores internal revenue). Q1 FY27 focused on supply chain integration; management guided 25% growth ("INR20 crores to INR40 crores over 3 years") with results expected from Q2 onwards.
- IVF Task Force: Dedicated specialist team created for gynecology/women's healthcare to deepen specialist engagement and brand adoption; too early to quantify but generating business.
- Brand Portfolio Scaling: Engine brand strategy delivering — 2 brands exceeding ₹100 crores (up from 1 in May-June 2023) and 40+ brands exceeding ₹10 crores (up from 32 in May-June 2023). Both new ₹10 crore club entries were organic.
- Inorganic Deals: BioZydus portfolio acquired for ₹7 crores — full acquisition cost recovered within first quarter; Noklot (cardiometabolic) launched in June 2026. No M&A planned in FY27 per earlier guidance.
- R&D Strengthening: Increased investment in process efficiencies, differentiated formulations, and talent; La Chandra Pharma Lab (31% stake) provides backward-integrated hormonal API supply covering
60-65% of captive needs; also serves external customers (65% of India's progesterone supply).
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Organic Revenue Growth | 15% for FY27 | Against anticipated IPM growth of ~10%; quarterly performance not annualized — full-year basis assessment |
| Inorganic Revenue Growth | 1.5-2% for FY27 | From Wokadine integration; organic + inorganic ≈ 17% total revenue growth |
| PAT Growth | 20% for FY27 | Reiterated despite raw material volatility; maintained through operating cost discipline |
| Wokadine Brand Growth | 25% over next 3 years | Build toward doubling brand from ~INR20 crores to INR40 crores |
| Medical Representative Additions | 200-250 per year (~6-8%) | Field force at 3,111 reps; 400 MRs added in Q4 FY26 being leveraged through FY27 |
| Hormonal Plant Asset Turnover | ~1x in FY27, 2-3x over 3 years | Domestic-led initially; international contribution from year 3 |
| International Business Share | Higher single-digit in 3-4 years | From current ~3%; India remains >90% of business |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Inflation | Geopolitical Southeast Asia disturbance from late February 2026; 70-90 days of inventory buffered Q1 but fresh purchases at higher costs from June could hit margins by ~100 bps; management mitigating through operating cost reductions |
| Margin Sustainability | FY27 EBITDA margin of 22% and PAT margin of 14.2% may not be extrapolated; management "cautious" on sustainability given volatile input costs and evolving cost environment |
| Hormone Facility Ramp-Up | Plant commercialized June 30, 2026; asset turnover <1x in first year creates under-recovery drag; international revenue only from FY28-29 after dossier approvals (12-18 month registration cycle) |
| Wokadine Integration Execution | First-quarter supply chain integration could not yet demonstrate the committed 25% growth trajectory; management confident but expects results "in coming quarters" |
Q&A Highlights
Industry Growth Outlook
- Question: What's driving the acceleration in IPM to double digits post-December 2025? (Pratik Dharamshi, Union Mutual Fund)
- Answer: Post-COVID normalization — industry returning to structural lower double-digit growth seen over last 20-25 years; management expects sustainable growth in the 9-11% band. (Nirav Mehta)
Margin Sustainability
- Question: With sustained 20%+ growth, is there scope for margin improvement or will incremental gains be reinvested? (Amey Chalke, JM Financials)
- Answer: Margin driven by product mix, operational efficiencies, and operating leverage; Q1 improvement from favorable mix and leverage, but environment remains volatile — cautious about extrapolating; endeavor to maintain similar range; FY27 guidance of 15% organic + 1.5-2% inorganic growth and 20% PAT unchanged. (Nirav Mehta)
Raw Material Impact & Timing
- Question: Given strong gross margins in Q1, can we expect higher raw material inflation impact in Q2? (Alankar Garude, Kotak)
- Answer: Geopolitical disturbances began late February 2026; company had 70-90 days of inventory, so minimal Q1 impact. Fresh purchases began June 2026 with possible ~100 bps hit; unpredictable duration; mitigating via operating cost reductions to hold 20% PAT guidance. (Nirav Mehta)
Wokadine Integration & Target
- Question: Wokadine sales appear down YoY — any corrective steps and status of 25% growth target? (Alankar Garude, Kotak)
- Answer: Q1 was supply chain integration quarter — critical for an India-focused company; committed 25% growth stands (INR20-40 crores over 3 years); results expected from coming quarters. External revenue standalone was INR28-30 crores; additional INR20 crores was Dr. Reddy's internal revenue. (Bhavin Bhagat)
Operating Leverage Over 2-3 Years
- Question: With no MR additions in FY27 and strong top-line growth, will operating leverage meaningfully expand margins? (Alankar Garude, Kotak)
- Answer: Added ~400 MRs in Q4 FY26 (now 3,111 total) being leveraged through FY27; ongoing ~6-8% annual field force additions (200-250 MRs) support operating leverage; 15% revenue/20% PAT guidance achievable in near term. (Nirav Mehta)
Cost Structure vs Larger Peers
- Question: Gross margins high but employee and other expenses higher than larger peers — how is this being optimized? (Gopal Bhatt, Baroda BNP Paribas AM)
- Answer: Employee cost reflects 1,000 MRs deployed in last 3.5 years (~35% of current field force); PCPM lower than peers currently, but operating leverage will play out. Other expenses largely sales promotion (UCPMP-linked, variable) and expected to trend lower as a percentage of revenue. (Bhavin Bhagat)
Organic vs Inorganic Growth Split
- Question: What portion of Q1 growth came from acquired brands vs organic? (Siddharth Goddanti, PWC)
- Answer: ~85% of incremental growth was organic, 15% inorganic; guidance of 25% growth applies to Wokadine specifically over next 2-3 years. Two new ₹10 crore-club brands are both organic. (Bhavin Bhagat, Nirav Mehta)
Hormone Plant Costs & Capitalization
- Question: What costs from the new hormone facility are sitting in the P&L pre-revenue? (Siddharth Goddanti, PWC)
- Answer: All pre-commercialization costs were capitalized (INR130 crores capex, depreciated over 20 years, ~INR6.5 crores annual); opex starts only post-commercialization (June 30, 2026). Hormone revenues already existed from Solan facility being transferred to new plant. (Bhavin Bhagat)
Growth Split: Volume vs Price vs New Launches
- Question: Can the 21% organic growth be split by volume, price, and new launches for the quarter? (Rahul Jeewani, IIFL)
- Answer: May-June figures: volume +6.3% (vs IPM 1.3%), new introductions +3.4% (vs IPM 2.9%), price +8.7% (vs IPM 5.6%); quarterly split similar in proportion to MAT data. (Nirav Mehta)
Hormone Facility Export Ramp-Up & API Backward Integration
- Question: What is the export trajectory from the new facility and status of La Chandra investment? (Rahul Jeewani, IIFL; Bhavika Singhvi, Niveshaay)
- Answer: Dossiers in final stage, bioequivalence done; tie-ups secured for U.K., emerging markets, and EU partners; filings by Nov-Dec 2026 with 12-18 month approval cycle; revenue from FY28-29. La Chandra (31% stake) supplies ~60-65% of captive hormonal API needs — progesterone, dydrogesterone, norethisterone, estradiol products. (Nirav Mehta)
Key Takeaway
Corona Remedies delivered a fourth consecutive strong quarter, with revenue up 21.9% YoY to ₹422 crores, EBITDA up 33.5% to ₹93 crores (22% margin, +190 bps), and PAT up 30.1% to ₹60 crores (14.2% margin) — nearly double the IPM growth of 11.6%. India business grew 22.7%, driven by volume growth 5x the market (6.3% vs 1.3%) and pricing power (8.7% vs 5.6%), with all four focused therapies (women's health, urology, cardiometabolic, pain) outperforming their respective market growth. Strategically, the company commercialized its INR130-crore EU GMP hormone facility, integrated Wokadine (first quarter was supply-chain focused with 25% three-year growth committed), and scaled its brand engine to 2 brands over ₹100 crores and 40+ brands over ₹10 crores. Management reaffirmed FY27 guidance of 15% organic revenue growth (17% with inorganic), 20% PAT growth, and expects IPM growth of 9-11%. Key watch points include ~100 bps potential raw material cost pressure from geopolitical disruptions, hormone plant under-recovery in year one, and Wokadine's ability to demonstrate its 25% growth trajectory from Q2 FY27 onwards.